Alliancebernstein L.P. cut its stake in Bruker Co. (NASDAQ:BRKR - Free Report) by 23.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,729,717 shares of the medical research company's stock after selling 819,195 shares during the period. Alliancebernstein L.P. owned about 1.80% of Bruker worth $160,016,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Bruker in the 4th quarter valued at about $63,378,000. Vaughan Nelson Investment Management L.P. grew its position in shares of Bruker by 140.3% during the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company's stock worth $66,930,000 after acquiring an additional 666,617 shares during the last quarter. Point72 DIFC Ltd grew its position in shares of Bruker by 4,875.9% during the third quarter. Point72 DIFC Ltd now owns 470,171 shares of the medical research company's stock worth $32,470,000 after acquiring an additional 460,722 shares during the last quarter. State Street Corp raised its position in Bruker by 9.6% in the 3rd quarter. State Street Corp now owns 3,627,300 shares of the medical research company's stock valued at $250,501,000 after purchasing an additional 318,808 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Bruker by 139.3% during the 4th quarter. JPMorgan Chase & Co. now owns 526,166 shares of the medical research company's stock worth $30,844,000 after purchasing an additional 306,282 shares during the period. Institutional investors and hedge funds own 79.52% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have commented on BRKR. Barclays dropped their price objective on shares of Bruker from $69.00 to $65.00 and set an "overweight" rating on the stock in a research note on Monday, February 10th. UBS Group initiated coverage on Bruker in a research note on Tuesday, December 10th. They set a "neutral" rating and a $66.00 price objective for the company. Guggenheim reiterated a "buy" rating on shares of Bruker in a research note on Monday, February 24th. Bank of America upped their price target on Bruker from $78.00 to $80.00 and gave the stock a "buy" rating in a research note on Friday, December 13th. Finally, Stifel Nicolaus cut their price objective on shares of Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a research report on Friday, February 14th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Bruker presently has an average rating of "Moderate Buy" and a consensus target price of $70.50.
Check Out Our Latest Research Report on Bruker
Bruker Price Performance
BRKR stock traded down $1.20 during midday trading on Friday, hitting $36.46. 4,101,408 shares of the stock were exchanged, compared to its average volume of 1,402,128. The stock's 50-day moving average price is $48.64 and its 200-day moving average price is $56.07. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The stock has a market cap of $5.53 billion, a price-to-earnings ratio of 47.97, a PEG ratio of 2.16 and a beta of 1.18. Bruker Co. has a fifty-two week low of $34.10 and a fifty-two week high of $91.34.
Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, beating analysts' consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. Research analysts predict that Bruker Co. will post 2.69 earnings per share for the current year.
Bruker Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.55%. The ex-dividend date was Monday, March 17th. Bruker's dividend payout ratio (DPR) is presently 26.32%.
Bruker Profile
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Further Reading
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
